HomeAI · summaries
Storia in 3 fonti
Cardiac drug developer Braveheart banks more than $382M in IPO
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Cardiac drug developer Braveheart banks more than $382M in IPO
Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.
- ·
endpoints.news
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3
Braveheart Bio prices $382.5M IPO, tapping Hengrui-licensed BHB-1893 to challenge Bristol Myers' Camzyos and Cytokinetics' Myqorzo in cardiomyopathy.
